ImmunoPrecise Antibodies (NASDAQ:IPA) Trading Up 15.5% – Here’s What Happened

Posted by Tyrone Williams on Jan 5th, 2025

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA – Get Free Report) shares traded up 15.5% on Friday . The stock traded as high as $0.54 and last traded at $0.52. 1,246,779 shares were traded during mid-day trading, an increase of 63% from the average session volume of 766,140 shares. The stock had previously closed at $0.45.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright lowered their price target on ImmunoPrecise Antibodies from $9.00 to $7.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th.

Read Our Latest Report on ImmunoPrecise Antibodies

ImmunoPrecise Antibodies Stock Performance

The stock’s 50-day moving average is $0.42 and its 200-day moving average is $0.65. The company has a current ratio of 1.01, a quick ratio of 0.82 and a debt-to-equity ratio of 0.36. The stock has a market cap of $16.15 million, a price-to-earnings ratio of -0.67 and a beta of 0.06.

Institutional Trading of ImmunoPrecise Antibodies

An institutional investor recently raised its position in ImmunoPrecise Antibodies stock. Renaissance Technologies LLC raised its position in ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA – Free Report) by 70.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 63,910 shares of the company’s stock after acquiring an additional 26,310 shares during the quarter. Renaissance Technologies LLC owned 0.24% of ImmunoPrecise Antibodies worth $65,000 at the end of the most recent quarter. 6.70% of the stock is owned by hedge funds and other institutional investors.

ImmunoPrecise Antibodies Company Profile

(Get Free Report)

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.